Open AccessBisphosphonate-induced osteoradionecrosis
Author(s) -
Ruchi Bhuyan,
Sanat Kumar Bhuyan,
Rajat Panigrahi,
Antarmayee Panigrahi
Publication year - 2013
Publication title -
journal of oral and maxillofacial pathology/journal of oral and maxillofacial pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.455
H-Index - 25
eISSN - 1998-393X
pISSN - 0973-029X
DOI - 10.4103/0973-029x.125221
Subject(s) - osteoradionecrosis , medicine , bisphosphonate , multiple myeloma , guideline , osteonecrosis of the jaw , complication , osteoporosis , presentation (obstetrics) , intensive care medicine , bone density conservation agents , case presentation , radiation therapy , surgery , general surgery , pathology , bone density
Bisphosphonates (BPs) are a class of agents used to treat osteoporosis and malignant bone metastasis. Despite these benefits, osteonecrosis of the jaws has recently emerged as a significant complication in a subset of patients receiving these drugs. This case presentation focuses on a 62-year-old man with a 3-year history of monthly use of Zometa (zolendronic acid) for treatment of multiple myeloma, resulting in BP-related osteoradionecrosis of the jaws (BRONJ). This new entity remains a challenge with diagnosis as well as treatment. The goal of this paper is to improve clinicians understanding and provide a guideline for establishing a stage-specific diagnosis and prevention of BRONJ.